Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The Challenges in Treating Rare and Orphan Diseases

Posted on March 21st, 2016 by

Pharma R&D

R_D_Solutions_Blog_Image_balloons_DIGITAL

Those outside of the drug and medical research communities often do not understand the complexities and challenges in developing therapeutic treatments for diseases that (more…)

Data Transparency in Pharmacovigilance: European regulators give increased access to adverse drug reactions

Posted on March 16th, 2016 by

Pharma R&D

ema logo

On 17 December 2015, the European Medicines Agency (EMA) adopted the revised policy on access to Eudravigilance. According to the press release, the EMA will give increased access to reports of adverse reactions (more…)

PV Poll: Processing of EMA MLM Data

Posted on March 16th, 2016 by

Pharmacovigilance

poll-shows

Over the past few months, we have posted blog entries about the EMA Medical Literature Monitoring (MLM) program, including a review of the EMA Annual Update and impressions of the launch phase closure report. (more…)

ACS San Diego Focuses on Computers + Chemistry

Posted on March 10th, 2016 by

Chemistry

R_D_Solutions_Blog_Image_two_scientists_DIGITAL

As I write this I am getting ready to travel to the 251st ACS National Meeting in San Diego, which starts this Sunday, March 13. I look forward to this year’s event which focuses on a theme that really resonates with me. Kenneth Merz, Jr., San Diego Thematic Program Chair for ACS notes that this year’s meeting: (more…)

POTUS, Data and How to Increase Your Likelihood of Success

Posted on March 10th, 2016 by

Pharma R&D

success

February 25 marked one year since the advent of the President’s Precision Medicine Initiative and the White House marked the anniversary by hosting a PMI Summit, including a panel discussion in which the POTUS himself (more…)

Catalyzing Decisions in Pharma-Biotech Collaborations

Posted on March 4th, 2016 by

Pharma R&D

collaboration

Despite large strides in technological and scientific progress, the cost to develop and release a new drug has escalated dramatically (1). At the same time, the number of generic drugs has grown in the last decade (2). In the U.S., 70% of (more…)

  1. 1
  2. …
  3. 56
  4. 57
  5. 58
  6. 59
  7. 60
  8. …
  9. 65


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.

n